Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics.

TL;DR: Current knowledge about the sensory transduction of pruritus is summarized detailing the local intercellular interactions that generate itch and the role of various pruritic mediators in the bidirectional crosstalk between cutaneous non-neuronal cells and sensory fibers is emphasized.

TL;DR: In this article , the authors summarized the updates and provided concise information, including classification, diagnosis, and management of urticaria, including the role of omalizumab, cyclosporine, H2 antihistamines, and other options.

TL;DR: This study identifies PTGS2 as a potential immune regulator and therapeutic target for chronic spontaneous urticaria, a debilitating skin disease, by analyzing gene expression and immune cell infiltration, and validating its role in mast cell degranulation and inflammation.

TL;DR: A healthy 34-year-old female presented with 1 day of diffuse urticaria and dermatographism unresponsive to loratadine and diphenhydramine and denied dyspnea, wheezing, emesis, or angioedema.

TL;DR: In a clinical practice setting, TCA use led to moderate improvement of residual gastrointestinal symptoms in IBD patients for whom escalation of IBD therapy was not planned.

TL;DR: Basophils and mast cells are the main target cells in chronic idiopathic urticaria and intrinsic defects of the anti‐IgE cross‐linking signalling pathway of basophils have been described in CIU.

TL;DR: The mainstay of treatment is avoidance of triggers, if identified, and the first-line pharmacotherapy is second-generation H1 antihistamines, which can be titrated to greater than standard doses.

TL;DR: The update of the international guidelines on urticaria will modify and improve the currently available guidelines in various areas, especially in therapy.